Is NBIX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Ingrezza is a durable, growing cash engine, with revenue (ttm) at ~$3.37 billion. The bear case rests on the dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. Analysts covering it are spread from $150.00 to $253.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $150.00, +10.5% from the $135.71 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Ingrezza is a durable, growing cash engine. Ingrezza net sales reached about $657 million in Q1 2026, up roughly 20 percent year over year on double-digit growth in new patient additions, and by September 2026 management had lifted full-year 2026 guidance to about $2.825 to $2.875 billion. The most optimistic analyst target on NBIX is $253.00, +86.4% from the $135.71 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. That reform is already scheduled: Ingrezza's Medicare negotiated price takes effect in 2029, management expects revenue to decline that year, and rival Austedo reaches its negotiated price two years earlier, in 2027. CNS drug development is also high-risk, and a single Phase 3 miss for the muscarinic or depression programs could sharply reset expectations. The Soleno acquisition adds integration and execution risk, with Vykat XR sales expected to be flat near term and safety reports under scrutiny, and the deal cut the cash balance to ~$390 million. The stock can be volatile around trial readouts, label decisions, and guidance updates; it fell ~24% over the three months to mid-October 2026. The most pessimistic published target is $150.00, +10.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Neurocrine Biosciences makes money primarily from Ingrezza (valbenazine), an oral VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease, which gene

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Ingrezza is a durable, growing cash engine) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a profitable, cash-generating Ingrezza franchise funding a deep CNS pipeline, plus two newer products in Crenessity and Vykat XR, at about 11 times forward earnings as of October 2026. The bear case is heavy reliance on one drug that faces a Medicare negotiated price in 2029, plus binary trial risk. Weigh how it fits your overall portfolio rather than timing a single entry.

Neurocrine Biosciences is a San Diego neuroscience biopharmaceutical company that develops and sells treatments for neurological, neuroendocrine, and psychiatric conditions. Its commercial products include Ingrezza for tardive dyskinesia, Crenessity for congenital adrenal hyperplasia, and Vykat XR for Prader-Willi syndrome, and it runs a pipeline spanning schizophrenia, depression, and other central nervous system disorders.

Ingrezza (valbenazine) is Neurocrine's flagship product, an oral VMAT2 inhibitor approved for tardive dyskinesia and for chorea associated with Huntington's disease. It is the company's largest revenue source, with about $657 million in net sales in Q1 2026 and full-year 2026 guidance raised to roughly $2.825 to $2.875 billion. Its Medicare negotiated price takes effect in 2029.